QYUNS-B(02509),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

02509 QYUNS-B

Closed The day following the Chung Yeung Festival 10-16 16:08:16

16.000

+0.500

+3.23%

High16.670	Low15.480	Vol638.00K
Open15.840	D1 Closing15.500	Amplitude7.68%
Mkt Cap3.57B	Tradable Cap3.57B	Total Shares223.00M
T/O10.15M	T/O Rate0.29%	Tradable Shares223.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"02509","market":"HK","secType":"STK","nameCN":"QYUNS-B","latestPrice":16,"timestamp":1792138096007,"preClose":15.5,"halted":0,"volume":638000,"delay":0,"changeRate":0.03225806451612903,"floatShares":223000000,"shares":223000000,"eps":1.41,"marketStatus":"Closed The day following the Chung Yeung Festival","change":0.5,"latestTime":"10-16 16:08:16","open":15.84,"high":16.67,"low":15.48,"amount":10152284,"amplitude":0.076774,"askPrice":16.61,"askSize":1000,"bidPrice":16,"bidSize":13200,"shortable":3,"etf":0,"ttmEps":2.802943,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1792459800000},"marketStatusCode":7,"adr":0,"listingDate":1710864000000,"exchange":"SEHK","adjPreClose":15.5,"openAndCloseTimeList":[[1792114200000,1792123200000],[1792126800000,1792137600000]],"volumeRatio":3.1170607790178075,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02509","defaultTab":"news","newsList":[{"id":"1167193163","title":"QYUNS-B Reports No Changes in Share Capital, Confirms Ample Public Float for September 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1167193163","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1167193163?lang=en_us&edition=fundamental","pubTime":"2026-10-07 17:05","pubTimestamp":1791363937,"startTime":"0","endTime":"0","summary":"Hong Kong-listed biopharmaceutical company Qyuns Therapeutics Co., Ltd. (QYUNS-B) has filed its Monthly Return for Equity Issuers for the period ended 30 September 2026, showing a stable capital...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02509"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672679263","title":"Qyuns Therapeutics' Oturkibart Shows Sustained Efficacy in Phase III Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2672679263","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672679263?lang=en_us&edition=fundamental","pubTime":"2026-10-02 14:18","pubTimestamp":1790921909,"startTime":"0","endTime":"0","summary":"Qyuns Therapeutics  reported sustained symptom improvements in a Phase III study of its Oturkibart treatment for adults with moderate-to-severe prurigo nodularis, according to a Friday exchange filing.At Week 24, 74.5% of Oturkibart patients saw reduced itching and 34.7% achieved clear or almost clear skin, compared with 29.0% and 11.1% for the placebo group, respectively. By Week 52, those efficacy rates climbed to 95.5% and 66.9% among patients continuing the treatment.The drug's safety profile was similar to the placebo, with no new long-term risks identified.Shares of the biopharmaceutical firm fell nearly 1% in recent trade.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4539","02509","BK1161","BK4139","LENZ","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118587788","title":"Qyuns Therapeutics Posts Strong Phase III Data for Oturkibart in Prurigo Nodularis; Results Spotlighted at EADV 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1118587788","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1118587788?lang=en_us&edition=fundamental","pubTime":"2026-10-02 08:26","pubTimestamp":1790900806,"startTime":"0","endTime":"0","summary":"Qyuns Therapeutics (QYUNS-B) reported that its China Phase III trial of Oturkibart (QX005N), a humanised anti-IL-4Rα monoclonal antibody, met primary and key secondary endpoints in adults with...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02509"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117582462","title":"QYUNS-B Releases Updated Director Line-Up and Board Committee Assignments","url":"https://stock-news.laohu8.com/highlight/detail?id=1117582462","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1117582462?lang=en_us&edition=fundamental","pubTime":"2026-09-22 22:21","pubTimestamp":1790086914,"startTime":"0","endTime":"0","summary":"QYUNS-B (official name: Qyuns Therapeutics Co., Ltd.) has published an updated roster of its Board of Directors and detailed the latest composition of its four specialised committees. The disclosure,...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02509"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127422140","title":"Hong Kong Stock Movers | QYUNS-B (02509) Jumps Over 9% in Morning Trade, BD Achievements Concentrated, First Product Sees Commercial Ramp-Up","url":"https://stock-news.laohu8.com/highlight/detail?id=1127422140","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1127422140?lang=en_us&edition=fundamental","pubTime":"2026-09-14 11:06","pubTimestamp":1789355176,"startTime":"0","endTime":"0","summary":"Shares of QYUNS-B (02509) surged more than 9% during Tuesday morning trading on the Hong Kong Stock Exchange. As of press time, the stock was up 5.60% at HK$17.15, with turnover reaching HK$26.71...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KCAI","BK4588","VXUS","BK1161","02509","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152623439","title":"QYUNS-B Reports Zero Share Movements, Affirms 25%+ Public Float in August 2026 HKEX Return","url":"https://stock-news.laohu8.com/highlight/detail?id=1152623439","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1152623439?lang=en_us&edition=fundamental","pubTime":"2026-09-04 10:42","pubTimestamp":1788489764,"startTime":"0","endTime":"0","summary":"Qyuns Therapeutics Co., Ltd. (QYUNS-B) has filed its Monthly Return for Equity Issuer and Hong Kong Depositary Receipts for the period ended 31 August 2026, confirming a stable capital structure and...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02509"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198410369","title":"Autoimmune Drug Leader Delivers on Long-Term Vision: QYUNS-B's Revenue Doubling and the Dual-Engine Growth Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=1198410369","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1198410369?lang=en_us&edition=fundamental","pubTime":"2026-08-21 15:00","pubTimestamp":1787295634,"startTime":"0","endTime":"0","summary":"The global autoimmune drug market continues to expand at a scale of hundreds of billions of US dollars, yet the penetration rate of biologics in the Chinese market remains below 30%, creating a stark...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02509","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661318892","title":"Qyuns Therapeutics (SEHK:2509) Stock Turns Profitable While Forecasts Cloud The Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2661318892","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661318892?lang=en_us&edition=fundamental","pubTime":"2026-08-21 01:26","pubTimestamp":1787246768,"startTime":"0","endTime":"0","summary":"Qyuns Therapeutics came into this earnings print with a profitable twelve month track record and a stock that has drifted, with the share price down about 6.6% over the past week but still modestly higher over three months. The headline this half is simple: the company delivered H1 2026 revenue of C¥424.1m and net income of C¥203.3m, which keeps the recent profitability story intact.\nThe tension for you as an investor sits between those solid trailing numbers and a stock valued at roughly...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2509/qyuns-therapeutics-shares/news/qyuns-therapeutics-sehk2509-stock-turns-profitable-while-for","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2509/qyuns-therapeutics-shares/news/qyuns-therapeutics-sehk2509-stock-turns-profitable-while-for","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4539","BK4139","BK4007","02509","LENZ","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131832342","title":"QYUNS-B (02509) Posts Interim Net Profit of RMB 203 Million, Reversing Year-Ago Loss as Its \"QYUNS 1.0\" Strategy Takes Shape","url":"https://stock-news.laohu8.com/highlight/detail?id=1131832342","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131832342?lang=en_us&edition=fundamental","pubTime":"2026-08-19 21:37","pubTimestamp":1787146658,"startTime":"0","endTime":"0","summary":"QYUNS-B (02509) has reported its financial results for the six months ended June 30, 2026, showing revenue of RMB 424 million, a 105.37% increase year-over-year. The company recorded a profit...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02509","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119580438","title":"QYUNS Interim: Licensing Windfall Drives Turn-Round to RMB198.57 Million Profit, Revenue Doubles","url":"https://stock-news.laohu8.com/highlight/detail?id=1119580438","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1119580438?lang=en_us&edition=fundamental","pubTime":"2026-08-19 21:27","pubTimestamp":1787146072,"startTime":"0","endTime":"0","summary":"Qyuns Therapeutics Co., Ltd. (abbrev. “QYUNS”) reported unaudited interim results for the six months ended 30 June 2026. Financial Highlights   • Revenue surged 105.4% year-on-year to RMB424.06...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"QYUNS Interim: Licensing Windfall Drives Turn-Round to RMB198.57 Million Profit, Revenue Doubles","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02509"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660542519","title":"QYUNS Therapeutics Posts HY Adjusted Profit of Rmb202.5 MLN","url":"https://stock-news.laohu8.com/highlight/detail?id=2660542519","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660542519?lang=en_us&edition=fundamental","pubTime":"2026-08-19 21:18","pubTimestamp":1787145504,"startTime":"0","endTime":"0","summary":"BRIEF-QYUNS Therapeutics Posts HY Adjusted Profit Of RMB202.5 MLNAug 19 (Reuters) - QYUNS Therapeutics HY Adjusted profit RMB202.5 MLN.QYUNS Therapeutics HY Revenue 424.1 MLN","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260819:nPLXSCVV4N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02509","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660251534","title":"Qyuns Therapeutics Hy Revenue 424.1 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2660251534","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660251534?lang=en_us&edition=fundamental","pubTime":"2026-08-19 21:17","pubTimestamp":1787145421,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260819:nPLXSCVV4N:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","02509"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660425130","title":"Qyuns Therapeutics Returns to Profit at RMB 198.57 Million in 1H FY26; Revenue More than Doubled to RMB 424.06 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2660425130","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660425130?lang=en_us&edition=fundamental","pubTime":"2026-08-19 21:16","pubTimestamp":1787145379,"startTime":"0","endTime":"0","summary":"Qyuns Therapeutics returns to profit at RMB 198.57 million in 1H FY26; revenue more than doubled to RMB 424.06 millionQyuns Therapeutics posted IFRS profit of RMB 198.57 million, swinging from a loss ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260819:nNDL26ZLv0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02509","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181928529","title":"Qyuns Therapeutics to Review 1H26 Interim Results at 19 August Board Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=1181928529","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1181928529?lang=en_us&edition=fundamental","pubTime":"2026-08-07 16:43","pubTimestamp":1786092218,"startTime":"0","endTime":"0","summary":"Qyuns Therapeutics Co., Ltd. has scheduled a board meeting for 19 August 2026 to consider and approve the Group’s interim results for the six-month period ended 30 June 2026, according to an...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02509"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655338363","title":"Qyuns Therapeutics Says China Clears Qx027n Trials for COPD","url":"https://stock-news.laohu8.com/highlight/detail?id=2655338363","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655338363?lang=en_us&edition=fundamental","pubTime":"2026-07-31 19:17","pubTimestamp":1785496623,"startTime":"0","endTime":"0","summary":"Qyuns Therapeutics says China clears QX027N trials for COPDChina’s NMPA drug review center cleared QX027N clinical trials in COPD and chronic rhinosinusitis with nasal polyps.The approvals add two res","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260731:nNDL5G63bf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02509","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655816363","title":"Qyuns Therapeutics Co - QX027n Obtains Two Clinical Trial Approvals for Copd and Chronic Rhinosinusitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2655816363","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655816363?lang=en_us&edition=fundamental","pubTime":"2026-07-31 19:16","pubTimestamp":1785496611,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260731:nFWN43X20U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","02509"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655841739","title":"Qyuns Therapeutics Partner Caldera to Merge with Synlogic","url":"https://stock-news.laohu8.com/highlight/detail?id=2655841739","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655841739?lang=en_us&edition=fundamental","pubTime":"2026-07-30 11:32","pubTimestamp":1785382325,"startTime":"0","endTime":"0","summary":"Qyuns Therapeutics  said its partner, Caldera Therapeutics, has agreed to merge with Synlogic in an all-stock transaction, according to a Wednesday Hong Kong bourse filing.The combined company is expected to list on the Nasdaq Capital Market under the ticker \"CALD.\"The deal is backed by a $278 million concurrent private placement to fund the development of QX030N/CLD-423 for ulcerative colitis, Crohn's disease and other immune-mediated diseases.Qyuns said it licensed global development and commercialization rights for QX030N/CLD-423 to Caldera in 2025 and currently holds about an 11.48% stake in the company.The merger is expected to close by early 2027, subject to shareholder, regulatory and other customary approvals.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","BK4139","LENZ","02509","BK4539","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154638743","title":"QYUNS-B (02509) Partner Caldera Therapeutics Plans Nasdaq Listing via Synlogic Merger with $278 Million Concurrent Fundraising Round","url":"https://stock-news.laohu8.com/highlight/detail?id=1154638743","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1154638743?lang=en_us&edition=fundamental","pubTime":"2026-07-29 20:09","pubTimestamp":1785326968,"startTime":"0","endTime":"0","summary":"QYUNS-B (02509) disclosed on July 29, 2026, that its partner, Caldera Therapeutics, Inc., has entered into a definitive merger agreement with Synlogic, Inc. (OTC: SYBX). This transaction is...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02509","BK4139","BK1161","SYBX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165846418","title":"QYUNS-B Updates on Partner Caldera: USD278.00 Million Private Placement Secured Ahead of Planned Nasdaq Listing via Merger with Synlogic","url":"https://stock-news.laohu8.com/highlight/detail?id=1165846418","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1165846418?lang=en_us&edition=fundamental","pubTime":"2026-07-29 20:03","pubTimestamp":1785326602,"startTime":"0","endTime":"0","summary":"Qyuns Therapeutics Co., Ltd. (“QYUNS-B”; together with subsidiaries, the Group) has released a voluntary announcement detailing material milestones at its partner, Caldera Therapeutics, Inc....","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02509"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139831720","title":"QYUNS-B Executes HK$15.99 On-Market Buyback; Issued Float Dips to 223.37 Million Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=1139831720","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1139831720?lang=en_us&edition=fundamental","pubTime":"2026-07-17 18:03","pubTimestamp":1784282612,"startTime":"0","endTime":"0","summary":"Qyuns Therapeutics Co., Ltd. (QYUNS-B) disclosed a minor share repurchase under Hong Kong’s Main Board Rule 13.25A for 17 July 2026. The company acquired 1,000 H-shares on the Stock Exchange at a...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02509"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.qyuns.net","stockEarnings":[{"period":"1week","weight":-0.0588},{"period":"1month","weight":-0.0274},{"period":"3month","weight":0.0006},{"period":"6month","weight":-0.2188},{"period":"1year","weight":-0.4386},{"period":"ytd","weight":-0.148}],"compareEarnings":[{"period":"1week","weight":-0.001},{"period":"1month","weight":-0.0213},{"period":"3month","weight":-0.0153},{"period":"6month","weight":-0.0754},{"period":"1year","weight":-0.0657},{"period":"ytd","weight":-0.0563}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Qyuns Therapeutics Co Ltd is a China-based company principally engaged in the research and development, manufacturing and commercialisation of biologic therapies for autoimmune and allergic diseases. The Company focuses on dermatology, respiratory, gastroenterology and rheumatology diseases. The Company's products include SAILEXIN, Oturkibart, and Crusekitug. The Company conducts its businesses in domestic and overseas markets.","exchange":"SEHK","name":"QYUNS-B","nameEN":"QYUNS-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"QYUNS-B(02509),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest QYUNS-B(02509) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"QYUNS-B,02509,QYUNS-B股票,QYUNS-B股票老虎,QYUNS-B股票老虎国际,QYUNS-B行情,QYUNS-B股票行情,QYUNS-B股价,QYUNS-B股市,QYUNS-B股票价格,QYUNS-B股票交易,QYUNS-B股票购买,QYUNS-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"QYUNS-B(02509),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest QYUNS-B(02509) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}